Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protagen to Support Pfizer Clinical Drug Development

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
Protagen have signed a collaboration agreement with Pfizer Inc.

Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.

Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protagen AG Achieves ISO 13485 Certification
The ISO 13485 certification covers the development, production and distribution of in-vitro diagnostics (IVD) for autoimmune diseases.
Wednesday, June 24, 2015
Protagen AG Appoints Bernhard Kirschbaum as New Board Member
Announcement follows recent strategic partnership between Protagen and Qiagen.
Thursday, January 08, 2015
Protagen Successfully Closes New Financing Round
QIAGEN N.V. joins existing investors.
Tuesday, December 16, 2014
Protagen AG and QIAGEN Collaborate
Protagen and QIAGEN partner to offer pharmaceutical companies an innovative companion diagnostic development platform for autoimmune disorders.
Monday, November 17, 2014
Protagen AG Sells Service Business
Protagen AG, Dortmund, divested its 100% subsidiary Protagen Protein Services GmbH (PPS), to Zukunftsfond Heilbronn.
Tuesday, July 02, 2013
Protagen counts on Kairos Expertise in Biobank- Management
Both companies plan long term partnership in which Protagen will profit from the administration and documentation of thousands of patient samples. Protagen will actively present and demonstrate the expertise of Kairos to the market.
Friday, March 30, 2012
Protagen Expands Cooperation with Bayer HealthCare
New collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis.
Thursday, December 08, 2011
Protagen at the European Antibody Congress 2010
Company experts will present the characterization of biotherapeutics with protein microarrays and the latest developments of GMP-compliant protein analysis.
Wednesday, November 03, 2010
Protagen AG and MicroDiscovery GmbH Cooperate in Biomarker Development
The cooperation is aimed to identify and validate biomarkers for medically relevant diseases.
Monday, October 25, 2010
Protagen Raises € 10.0 Million for Diagnostic Developments
Funds will be utilized for the targeted expansion of the business unit Diagnostics and the clinical validation of proprietary diagnostic marker proteins.
Thursday, September 09, 2010
Key Patent of Protagen Granted in Japan
The patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology.
Friday, August 13, 2010
Evaluation of UNIarray® for Infectious Disease Diagnostics
Protagen and Mikrogen close their collaboration agreement for the identification of typical autoantibody signatures in infectious diseases.
Thursday, July 08, 2010
Protagen Deepens Cooperation with Bayer Schering Pharma
Both the companies announce the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis.
Thursday, June 10, 2010
UNIchip Protein Biochips from Protagen Identify Significant Off-target binding for TNF-alpha Inhibitors
Findings could explain side effects seen with these biological drugs for treating rheumatic diseases.
Thursday, April 03, 2008
UNIchip protein biochips from Protagen identify significant off-target binding for TNF-alpha inhibitors
Tumor Necrosis Factor-a inhibitors used to treat rheumatic diseases may bind to a significant number of proteins other than their main target, according to the results of an in vitro study published in Analytical and Bioanalytical Chemistry.
Monday, March 31, 2008
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!